Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 325-330

  Zhou, Xiaoling ^a   Yang, Xu Yu ^a   Popescu, Nicholas C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; DLC1; Inhibition prostate tumor growth in vivo; RhoA activity; SAHA; Tumor suppressor gene

Indexed keywords

ANTINEOPLASTIC AGENT; DLC1 TUMOR SUPPRESSOR PROTEIN; HISTONE DEACETYLASE INHIBITOR; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOTOXICITY; DEACETYLATION; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; HISTONE ACETYLATION; IN VIVO STUDY; MALE; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BALB 3T3 CELLS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA METHYLATION; DRUG EVALUATION, PRECLINICAL; GTPASE-ACTIVATING PROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; PROSTATIC NEOPLASMS; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 84862808307     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.158     Document Type: Article

References (26)

1. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
2. Yuan B.Z., Miller M.J., Keck C.L., Zimonjic D.B., Thorgeirsson S.S., Popescu N.C. Cloning, characterization and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homogous to rat RhoGAP. Cancer Res. 1998, 58:2196-2199.
3. Goodison S., Yuan J., Sloan D., Kim R., Li C., Popescu N.C., Urquidi V. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005, 65:6042-6053.
4. Durkin M.E., Yuan B.Z., Zhou X., Zimonjic D.B., Lowy D.R., Thorgeirsson S.S., Popescu N.C. DLC-1: a Rho GTPase-activating protein and tumour suppressor. J. Cell. Mol. Med. 2007, 11:1185-1207.
5. Xue W., Krasnitz A., Lucito R., Sordella R., Vanaelst L., Cordon-Cardo C., Singer S., Kuehnel F., Wigler M., Powers S., Zender L., Lowe S.W. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 2008, 22:1439-1444.
6. Guan M., Zhou X., Soulitzis N., Spandidos D.A., Popescu N.C. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin. Cancer Res. 2006, 12:1412-1419.
7. McGuire C., Lee J. Brief review of Vorinostat. Clin. Med. Insights: Therapeutics 2010, 2:83-87.
8. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3:166-179.
9. Guan M., Tripathi V., Zhou X., Popescu N.C. Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines:prospects for gene therapy. Cancer Gene Ther. 2008, 15:371-381.
10. Ullmannova-Benson V., Guan M., Zhou X., Tripathi V., Yang X.Y., Zimonjic D.B., Popescu N.C. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 2009, 23:383-390.
11. Kim T.Y., Kim I.S., Jong H.S., Lee J.W., Kim T.Y., Jung M., Bang Y.J. Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells. Exp. Mol. Med. 2008, 40:639-646.
12. Cheng, A.M. Levin, Y.C. Tai, S. Plummer, G.K. Chen, C. Neslund-Dudas, G. Casey, B.A. Rybicki, J.S. Witte, Copy number alterations in prostate tumors and disease aggressiveness, Genes Chromosomes Cancer 51 (2012) 66-76.
13. Zhou X., Yang X-Y., Popescu N.C. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamicacid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. Int. J. Oncol. 2010, 36:999-1005.
14. Sramkoski R.M., Pretlow T.G., Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.S., Marengo S.R., Rhim J.S., Zhang D., Jacobberger J.W. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev. Biol. Anim. 1999, 35:403-409.
15. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60:5165-5170.
16. X.-Y. Yang, M. Guan, D. Vigil, C.J. Der, D.R. Lowy, N.C. Popescu, p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth suppressing activities. Oncogene 28 (2009) 1401-1409.
17. Sahai E., Marshall C.J. RHO-GTPases and cancer. Nat. Rev. Cancer 2002, 2:133-142.
18. Jaffe A.B., Hall A. Rho GTPases in transformation and metastasis. Adv. Cancer Res. 2002, 84:57-80.
19. Vigil D., Cherfils J., Rossman K.L., Der C.J. Ras superfamily GEFs andGAPs: validated and tractable targets for cancer therapy?. Nat. Rev. Cancer 2010, 10:842-857.
20. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment ofcancer. Nat. Rev. Drug Discov. 2002, 1:287-299.
21. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
22. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
23. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009, 280:192-200.
24. Richon V.M., Garcia-Vargas J., Hardwick J.S. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009, 280:201-210.
25. Lahoz A. Hall, DLC1: a significant GAP in the cancer genome. Genes Dev. 2008, 22:1724-1730.
26. Cao X., Voss C., Zhao B., Kaneko T., Li S.S-C. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensin control cell migration and transformation. Proc. Natl. Acad. Sci. USA 2012, 109. 1455-146.